Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Hydroxychloroquine / azithromycin in COVID-19: The association between time to treatment and case fatality rate
Accinelli et al., Travel Medicine and Infectious Disease, doi:10.1016/j.tmaid.2021.102163
Accinelli et al., Hydroxychloroquine / azithromycin in COVID-19: The association between time to treatment and case fatality.., Travel Medicine and Infectious Disease, doi:10.1016/j.tmaid.2021.102163
Sep 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 1,265 outpatients in Peru treated with HCQ+AZ showing mortality associated with treatment delay. Mortality was six times lower than the national average.
Accinelli et al., 14 Sep 2021, peer-reviewed, 6 authors, this trial uses multiple treatments in the treatment arm (combined with AZ) - results of individual treatments may vary.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Journal Pre-proof Hydroxychloroquine / azithromycin in COVID-19: The association between time to treatment and case fatality rate Roberto Alfonso Accinelli, Grisel Jesús Ynga-Melendez, Juan Alonso Leon-Abarca, Lidia Marianella López, Juan Carlos Madrid-Cisneros, Juan Diego Mendoza-Saldaña PII: S1477-8939(21)00204-0 DOI: https://doi.org/10.1016/j.tmaid.2021.102163 Reference: TMAID 102163 To appear in: Travel Medicine and Infectious Disease Received Date: 26 April 2021 Revised Date: 27 August 2021 Accepted Date: 9 September 2021 Please cite this article as: Accinelli RA, Ynga-Melendez GriselJesú, Leon-Abarca JA, López LM, MadridCisneros JC, Mendoza-Saldaña JD, Hydroxychloroquine / azithromycin in COVID-19: The association between time to treatment and case fatality rate, Travel Medicine and Infectious Disease (2021), doi: https://doi.org/10.1016/j.tmaid.2021.102163. This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2021 Published by Elsevier Ltd. Credit author statement Roberto Alfonso Accinelli: Conceptualization, resources, data curation, writing (Original Draft), writing (Review & Editing), supervision,project administration,funding acquisition. Grisel Jesús Ynga-Melendez: Investigation, resources, data curation, writing (Original Draft), funding acquisition. Juan Alonso Leon-Abarca: Methodology, software, validation, formal analysis, investigation, writing (Original Draft), writing (Review & Editing),visualization. Lidia Marianella Lopez: Methodology, software, validation, formal analysis, investigation, writing (Original Draft), writing (Review & Editing),visualization. Juan Carlos Madrid-Cisneros: Investigation, writing (Original Draft), visualization. Jo ur na lP re -p r oo f Juan Diego Mendoza-Saldaña: Investigation, writing (Original Draft), visualization. 1 Hydroxychloroquine / Azithromycin in COVID-19: the association 2 between time to treatment and case fatality rate. 3 4 Authors: 5 Roberto Alfonso Accinelli 6 Abarca 7 Mendoza-Saldaña 2, c 8 1 9 Peru , Grisel Jesús Ynga-Melendez 4,b , Juan Alonso Leon- , Lidia Marianella López 1,b , Juan Carlos Madrid-Cisneros 4,b, Juan Diego of 1,b 1,2,3,a -p ro Instituto de Investigaciones de la Altura. Universidad Peruana Cayetano Heredia, Lima, 10 2 11 Peru 12 3 Hospital Cayetano Heredia 13 4 Centro Materno-Infantil Tahuantinsuyo Bajo, Lima, Peru 14 a Pulmonologist and MPH 15 b MD 16 c Medical student 17 Corresponding author: Roberto Alfonso Accinelli 18 Phone: (+51) 998119480 Email: roberto.accinelli@upch.pe 19 Address: Instituto de Investigaciones de la Altura. Av. Honorio Delgado 262, San Martin 20 de Porres, Lima 15102, Peru Jo ur na lP re Facultad de Medicina Alberto Hurtado, Universidad Peruana Cayetano Heredia, Lima, 21 22 Abstract word count: 197. Number of words: 4581. References: 70. 23 1 24 ABBREVIATIONS 25 Hydroxychloroquine (HCQ); Azithromycin (AZIT); Severe acute respiratory..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit